Heidi Henson
Director/Board Member at PERSPECTIVE THERAPEUTICS, INC.
Net worth: 123 178 $ as of 2024-03-30
Profile
Heidi Henson is currently serving as the Director at Cend Therapeutics, Inc. since 2019.
She is also an Independent Director at Lisata Therapeutics, Inc. since 2022, an Independent Director at Perspective Therapeutics, Inc. since 2023, and an Independent Non-Executive Director at PepGen Inc. since 2021.
Additionally, she is a Member of The Association of Bioscience Financial Officers.
In her former positions, Ms. Henson worked as the Director-Finance at Anadys Pharmaceuticals, Inc. She also held the position of Principal at Fair Isaac Corp.
and HNC Software, Inc. Furthermore, she served as the Controller at La Jolla Pharmaceutical Co. from 2004 to 2005.
Ms. Henson worked as an Auditor at PricewaterhouseCoopers LLP and as the Chief Financial Officer & Secretary at Zeta Acquisition Corp.
III.
From 2012 to 2018, she held the role of Chief Financial Officer & Secretary at Araxes Pharma LLC and Wellspring Biosciences LLC.
She was also the Secretary, Chief Financial & Accounting Officer at Kura Oncology, Inc. from 2014 to 2018.
Additionally, she served as the Vice President-Finance at Intellikine LLC from 2011 to 2012.
Ms. Henson was the Chief Financial Officer at Imbria Pharmaceuticals, Inc. from 2019 to 2020 and at Respivant Sciences, Inc. from 2018 to 2019.
She also held the position of Chief Financial Officer at Pardes Biosciences, Inc. from 2021 to 2023.
Moreover, she served as the Chief Financial Officer at San Diego Children's Choir.
Ms. Henson completed her undergraduate degree at the University of San Diego.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2024-01-08 | 39,480 ( 0.48% ) | 123 178 $ | 2024-03-30 | |
PEPGEN INC.
-.--% | 2023-04-14 | 0 ( -.--% ) | - $ | 2024-03-30 |
| 2024-04-01 | 0 ( -.--% ) | - $ | 2024-03-30 |
Heidi Henson active positions
| Companies | Position | Start |
|---|---|---|
| PEPGEN INC. | Director/Board Member | 2021-06-30 |
| LISATA THERAPEUTICS, INC. | Director/Board Member | 2022-09-14 |
| PERSPECTIVE THERAPEUTICS, INC. | Director/Board Member | 2023-05-31 |
Cend Therapeutics, Inc.
 Cend Therapeutics, Inc. BiotechnologyHealth Technology Cend Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of therapies for solid tumor cancers. Its offers CendR Platform, which provides a targeted tissue penetration capability to specifically enhance drug delivery to tumors. Its lead compound CEND-1 seeks out tumors and activates the CendR transport pathway. The company was founded by Erkki Ruoslahti in 2016 and is headquartered in San Diego, CA. | Director/Board Member | 2019-01-30 |
The Association of Bioscience Financial Officers
 The Association of Bioscience Financial Officers Miscellaneous Commercial ServicesCommercial Services The Association of Bioscience Financial Officers operates as a national networking group for biotechnology, med tech and bioscience financial officers. The company was founded in 1988 and is headquartered in Menlo Park, CA. | Corporate Officer/Principal | - |
Former positions of Heidi Henson
| Companies | Position | End |
|---|---|---|
| PARDES BIOSCIENCES, INC. | Director of Finance/CFO | 2023-08-29 |
Imbria Pharmaceuticals, Inc.
 Imbria Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Imbria Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company developing novel therapies that restore cellular energy deficits. It focuses on restoring or improving the cell?s ability to produce energy where energy imbalances are at the root of disease, including cardiovascular diseases and inborn errors of metabolism. The company was founded by Andrew Levin and David-Alexandre C. Gros in 2018 and is headquartered in Boston, MA. | Director of Finance/CFO | 2020-06-30 |
Training of Heidi Henson
| University of San Diego | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 5 |
|---|---|
| FAIR ISAAC CORPORATION | Technology Services |
| KURA ONCOLOGY, INC. | Health Technology |
| PEPGEN INC. | Health Technology |
| LISATA THERAPEUTICS, INC. | Health Technology |
| PERSPECTIVE THERAPEUTICS, INC. | Health Technology |
| Private companies | 10 |
|---|---|
La Jolla Pharmaceutical Co.
 La Jolla Pharmaceutical Co. Pharmaceuticals: MajorHealth Technology La Jolla Pharmaceutical Co. operates as a biopharmaceutical company. It engages in the discovery, development and commercialization of therapies intended to improve outcomes in patients suffering from life-threatening diseases. Its products portfolio include GIAPREZA and XERAVA. The company was founded in 1989 and is headquartered in San Diego, CA. | Health Technology |
HNC Software, Inc.
 HNC Software, Inc. Packaged SoftwareTechnology Services HNC Software, Inc. provided predictive software solutions. It offered these services to service industries including companies in the insurance, financial services, telecommunications, e-commerce and retail industries. Company also provided analytical and decision management software applications and tools. HNC Software is located in San Diego, CA. | Technology Services |
PricewaterhouseCoopers LLP
 PricewaterhouseCoopers LLP Miscellaneous Commercial ServicesCommercial Services PricewaterhouseCoopers LLC provides assurance, tax and advisory services. Its services include audit and assurance, consulting, deals, human resources, legal, tax, and family business. The firm also offers accountability, risk management, structuring, mergers and acquisitions, and performance and process improvement. The company was founded in 1998 and is headquartered in Buffalo, NY. | Commercial Services |
Anadys Pharmaceuticals, Inc.
 Anadys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Anadys Pharmaceuticals, Inc. develops and manufactures novel small molecule medicines. It engages in developing novel medicines in the areas of hepatitis C and oncology. The firm develops ANA598, a direct-acting antiviral for the treatment of hepatitis C. The company was founded by Stelios B. Papadopoulos and Kleanthis G. Xanthopoulos in 1992 and is headquartered in Little Falls, NJ. | Health Technology |
Zeta Acquisition Corp. III
 Zeta Acquisition Corp. III MiscellaneousMiscellaneous Zeta Acquisition Corp. III operates as a blank check company. It was organized as a vehicle to investigate and, if such investigation warrants, acquire a target company or business seeking the perceived advantages of being a publicly held corporation. The firm will not restrict its potential candidate target companies to any specific business, industry or geographical location and, thus, may acquire any type of business. The company was founded on November 16, 2007 and is headquartered in Des Moines, IA. | Miscellaneous |
Intellikine LLC
 Intellikine LLC Pharmaceuticals: MajorHealth Technology Intellikine LLC develops and manufactures small molecule drugs for the treatment of cancer. The company focused on the development of potent, selective small molecule inhibitors of the PI3K/Akt/mTOR pathway for the treatment of cancer, inflammation and autoimmune disorders. Intellikine was founded on May 2nd, 2007 and is headquartered in La Jolla, CA. | Health Technology |
Pardes Biosciences, Inc.
 Pardes Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Pardes Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering, developing and commercializing novel therapeutics to treat and prevent viral diseases. It also focuses on developing novel drugs to solve pandemic-sized problems like the coronavirus disease. The company was founded by Uri A. Lopatin and Lee D. Arnold on February 27, 2020 and is headquartered in Carlsbad, CA. | Health Technology |
Cend Therapeutics, Inc.
Cend Therapeutics, Inc. BiotechnologyHealth Technology Cend Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of therapies for solid tumor cancers. Its offers CendR Platform, which provides a targeted tissue penetration capability to specifically enhance drug delivery to tumors. Its lead compound CEND-1 seeks out tumors and activates the CendR transport pathway. The company was founded by Erkki Ruoslahti in 2016 and is headquartered in San Diego, CA. | Health Technology |
Imbria Pharmaceuticals, Inc.
Imbria Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Imbria Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company developing novel therapies that restore cellular energy deficits. It focuses on restoring or improving the cell?s ability to produce energy where energy imbalances are at the root of disease, including cardiovascular diseases and inborn errors of metabolism. The company was founded by Andrew Levin and David-Alexandre C. Gros in 2018 and is headquartered in Boston, MA. | Health Technology |
The Association of Bioscience Financial Officers
The Association of Bioscience Financial Officers Miscellaneous Commercial ServicesCommercial Services The Association of Bioscience Financial Officers operates as a national networking group for biotechnology, med tech and bioscience financial officers. The company was founded in 1988 and is headquartered in Menlo Park, CA. | Commercial Services |
- Stock Market
- Insiders
- Heidi Henson
